A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 48-WEEK, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LOSMAPIMOD IN TREATING PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Registry ID

1821-FSH-301

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

FULCRUM THERAPEUTICS

Start date

2024-04-03

Completion date

2025-01-06

Last update

2022-08-17

Conditions

• MUSCULAR DYSTROPHY

Related clinical trials

• A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ACE-083 IN PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

View on source registry